Body Part, Organ, or Organ Component
Amber Therapeutics Raises $100M for Closed-Loop Neuromodulation Implant for Urinary Incontinence
Amber Therapeutics, urinary incontinence, neuromodulation, closed-loop implant, funding, series A round, pelvic pudendal nerve, mixed incontinence, U.S. regulatory approval.
Biomea’s Early-Stage Diabetes Drug Placed on Full Clinical Hold, Stock Plummets
Biomea, diabetes, clinical hold, FDA, BMF-219, liver toxicity, stock crash
Gilead and Cartography Collaborate to Identify Novel Antigen Targets for Cancer Therapy
Gilead Sciences, Cartography Biosciences, cancer therapy, antigen targets, triple-negative breast cancer, lung adenocarcinoma, ATLAS platform, SUMMIT platform, oncology, drug development.
Ozempic Reduces Mortality Risk by 20% in Diabetes Patients with Chronic Kidney Disease
** Ozempic, Novo Nordisk, diabetes, chronic kidney disease, mortality risk, cardiovascular deaths, kidney failure, semaglutide, Wegovy, obesity treatment
Tango Pauses Clinical Trials of Promising Solid Tumor Treatment Due to Liver Toxicity Concerns
Tango Therapeutics, solid tumor treatment, clinical trials, liver toxicity, drug development, cancer research, treatment side effects, patient safety.
Crinetics’s Atumelnant Shows Promising Early Results in Congenital Adrenal Hyperplasia Treatment
Crinetics, Atumelnant, congenital adrenal hyperplasia, early data, treatment, clinical trial, cortisol, androgens, ACTH, adrenal glands.
Endeavor’s $132.5 Million Funding Accelerates Fibrotic Lung and Solid Tumor Therapeutic Development
Endeavor, funding, fibrotic lung, solid tumors, therapeutic development, medical research, healthcare innovation.
Daiichi Sankyo Invests $1 Billion to Expand German Facility for Precision Cancer Antibody-Drug Conjugates
Daiichi, Sankyo, Antibody-Drug Conjugates
Eicos Sciences’ Aurlumyn: First FDA-Approved Treatment for Severe Frostbite Reduces Amputation Risk
Aurlumyn, Eicos, Amputation, Sciences’, iloprost, severe frostbite
FDA Awaits Final Decision on Madrigal’s Resmetirom for NASH Treatment with Priority Review and NDA Acceptance Set for March 14, 2024
Nonalcoholic Steatohepatitis, resmetirom, United States Food and Drug Administration, New Drug Application, Priority Review, Fibrosis, Liver, Liver, Madrigal’s, March 14, 2024